Contraindicated (1)bortezomib will raise the degree or influence of mavacamten by influencing hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or reasonable CYP2C19 inhibitors could raise mavacamten systemic publicity, leading to coronary heart failure as a consequence of systolic dysfunction. chloramphenicol will improve the stage or effect of bortezomib by influencing hepa... https://andrewl776zku9.anchor-blog.com/profile